Drugs / MT1002
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05323136 | Apr → Jun 2022 | acute coronary syndrome | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04116840 | Apr → Aug 2019 | — | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06533358 | Feb → Dec 2024 overdue | acute coronary syndrome | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT04723186 | Dec 2020 → Aug 2023 | acute coronary syndrome | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT1002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05323136 ↗ |
| Action | Inhibit | “a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa receptor antagonist” NCT04723186 ↗ |
| Modality | Peptide | “32-amino acid synthetic peptide” NCT04723186 ↗ |
| Route | Intravenous | “Study drug will be administered by an intravenous bolus dose followed by an infusion of 4 hours.” NCT04116840 ↗ |